Gujarat Themis Biosyn Ltd Growth Catalysts - SOIC x StockScans Report
as of Aug 2026
- MBJ acquisition - Definitive agreement signed 22 May 2026 to buy 100% of MicroBiopharm Japan for JPY 2,150 crore (\~₹1,300 crore), expected to close Q2 FY27. MBJ adds \~₹570 crore revenue (FY26E) and a 7-8 year jump start in fermentation-based CDMO, roughly tripling GTBL's revenue base at close.
- Sanofi brand portfolio - Asset Purchase Agreement signed 23 April 2026 for 13 anti-TB and anti-infective brands across 55+ countries, with Euro 62 million FY25 net sales, closing expected by December 2026. The Euro 158 million (\~₹1,700 crore) deal adds a revenue stream nearly 2.5x GTBL's current annual revenue, with margin upside from integrating GTBL's own APIs.
- Fermentation capacity expansion - Vapi capacity doubled from 450 KL to 990 KL, with first commercial Rifamycin-S and Rifamycin-O production starting 18 October 2025. After being sold out for \~3 years, the company expects output from expanded capacity partially in Q2 FY27 and fully in H2 FY27 - the first volume growth since the constraint began.
- API forward integration - Dedicated API block commissioned with three production streams; Rifapentine, Rifaximin and Rifampicin API production all underway as of Q1 FY27. The \~₹200 crore fermentation and API capex is expected to generate 1.4x-1.5x asset turn, converting the company from intermediates-only to higher-margin API sales into US and Europe.
- Hybrid wind-solar power - \~18 MW captive hybrid power plant in Gujarat, Phase 1 live September 2026, Phase 2 \~2 months later. Power at significantly lower price directly improves EBITDA margins on the expanded fermentation capacity.
- R&D facility expansion - Phase 1 of new R&D facility commissioned during FY25, with new R&D and API units up and running as of Q1 FY27. The facility supports a substantially expanded product portfolio of new intermediates and APIs, funded by R&D spend of \~12% of FY25 sales.
- Optimus Drugs restart - Dispute resolved and business restarting after 6-9 months without supplying Optimus, during which GTBL easily sold out capacity. Restarting this customer adds demand on top of the new fermentation capacity, with the company now selling intermediates to anyone in India or abroad manufacturing these APIs.